期刊文献+

复合磷酸酯酶及其在肝脏疾病中的应用

Application of phosphoesterase complex in the treatment of liver disease
原文传递
导出
摘要 肠道菌群在脂肪性肝病、肥胖及代谢性疾病的发生和发展过程中具有重要作用,复合磷酸酯酶能促进肠道未消化食物的分解,促进由细菌不完全分解产生的有毒物质及有害气体排出,维持肠道菌群平衡,降低内毒素等物质对肝脏的影响,同时又可以缓解患者腹胀等不适症状。本文简要综述复合磷酸酯酶的作用机制及其在肝脏疾病中的应用。 Intestinal microbiota plays an important role in the development and progression of fatty liver,obesity and metabolic disease.Phosphoesterase complex can promote the undigested foods in gut broken down,and make the toxic substances and harmful gases produced by bacteria to decompose.So it can balance intestinal microbiota,reduce the effects of endotoxin on the liver and release the bloating discomfort and other symptoms.This review describes the mechanism and the clinical application of phosphoesterase complex.
出处 《世界临床药物》 CAS 2016年第9期639-642,共4页 World Clinical Drug
关键词 复合磷酸酯酶 肠道菌群 肝脏疾病 代谢性疾病 phosphoesterase complex intestinal microbiota liver disease metabolic disease
  • 相关文献

参考文献25

  • 1杨丽,牛晓丽,王连磊.复合磷酸酯酶肠溶片在肝病治疗方面的应用概述[J].药学研究,2013,32(11):665-666. 被引量:4
  • 2李晓宇,田字彬,何西钢,刘有信,胡晓飞,崔铮.复合磷酸酯酶在肝病领域的临床应用进展[J].世界华人消化杂志,2014,22(29):4424-4429. 被引量:1
  • 3Matthew JB, Nigel TP. The human gut microbiome in health and disease [J]. Integr Med (Encinitas), 2014, 13 (6) : 17-22. 被引量:1
  • 4Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance [J]. Diabetes, 2007, 56(7) : 1761-1771. 被引量:1
  • 5Fouts DE, Torralba M, Nelson KE, et aL Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease [J]. J Hepatol, 2012, 56 (6) : 1283-1292. 被引量:1
  • 6Maneesh D, Higgins PD, Middha S, et al. The human gut microbiome: current knowledge, challenges and future directions [J]. Transl Res, 2012, 160 (4) : 246-257. 被引量:1
  • 7Federico A, Dallio M, Godos J, et al. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence [J]. Transl Res, 2016, 167 (1) : 116-124. 被引量:1
  • 8Musso G, Gambino R, Cassader M. Obesity, diabetes and gutmicrobiota[J]. Diabetes Care, 2010, 33 (10): 2277-2284. 被引量:1
  • 9Konturek PC, Haziri D, Brzozowski T, et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases [J]. J Physiol Pharmacol, 2015, 66 (4) : 483-491. 被引量:1
  • 10Cariello R, Federico A, Sapone A, et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damagep [J]. Diq Liver Dis, 2010, 42 (3) : 200-204. 被引量:1

二级参考文献71

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部